Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral develops devices for unmet medical needs. Sepsis occurs in 1.7M Americans/year causing 250K deaths, often caused by endotoxin. Our devices measure and remove endotoxin from the bloodstream. An FDA confirmatory trial is underway. Dialco, a Spectral sub, offers SAMI, a novel instrument for renal replacement, cleared by FDA. Dialco is seeking FDA approval for DIMI a unique home dialysis enabler. These devices have large commercial potential


TSX:EDT - Post by User

Comment by MMABStraderon May 05, 2021 2:30pm
113 Views
Post# 33133477

RE:RE:RE:RE:Spectral mgnt may requst an extension for a U.S. listing

RE:RE:RE:RE:Spectral mgnt may requst an extension for a U.S. listing
I agree with you that the range for a reverse split for shareholder approval should be lowered to 1:5 assuming that the range shareholders approve is "cut in stone" and forces the company to not do a reverse split below what shareholders approve. Personally, I'm more concerned with the upper number of 1:20 and cringe when I think a reverse split would be that high.
 
I have to disagree with you in that I would like to see a significant announcement (milestone) before they start the application process. We are awaiting several significant announcements. Maybe it makes the most sense strategically to announce a milestone event and start the application process for a U.S. listing on the same day?
 
As for spinning off Dialco... I don't think that would occur before the in-home test is completed and we know the results i.e. May/June 2022.
 
Best case scenario ... the Phase III (B) test is halted after a mid test update and efficacy is such that Spectral is able to apply earlier than anticipated for FDA approval of PMX. (Though I'm not holding my breath on this one.)
<< Previous
Bullboard Posts
Next >>